177Lu-PSMA-I&T在FDG阳性mCRPC中的真实世界结局:缓解与生存相关因素
该回顾性研究纳入25例[18F]FDG阳性mCRPC患者,分析双示踪PET参数与[177Lu]Lu-PSMA-I&T治疗缓解及生存的关系,发现PSMA SUVmean及PSMA/FDG SUVmean比值与PSA30缓解相关,肿瘤负荷参数和生化指标与预后相关。
要点
- PSMA SUVmean>10.23及PSMA/FDG SUVmean比值>2.08可能预测PSA30缓解。
- 高ALP、PSMA MTV、PSMA TLU及FDG MTV与较短rPFS相关。
- 治疗前血红蛋白、ALP、PSA及PSMA MTV、TLU、FDG MTV与OS相关。
核心结论
- 在FDG阳性mCRPC患者中,全身[68Ga]Ga-PSMA-11 SUVmean高于10及PSMA/FDG SUVmean比值大于2可能有助于识别可能达到PSA下降至少30%的患者。
- 影像体积参数或已知生化标志物计算的肿瘤负荷具有预后意义。
研究设计与样本
- 回顾性评估在[177Lu]Lu-PSMA-I&T治疗前接受[68Ga]Ga-PSMA-11和[18F]FDG PET/CT的mCRPC患者,仅纳入FDG阳性患者。
- 采用半自动分割工具测量双PET/CT的全身SUVmax、SUVmean、MTV和TLU。
- PSA缓解定义为下降≥30%和≥50%,影像学缓解于末次 cycle 后两个月根据RECIST 1.1和/或PSMA PET进展(PPP)标准评估。
- 共纳入25例FDG阳性接受[177Lu]Lu-PSMA-I&T治疗的患者。
主要发现
- PSA30和PSA50缓解分别见于11/25(44%)和9/25(36%)患者。
- 单因素分析中,[68Ga]Ga-PSMA-11 SUVmean(p=0.022)和[68Ga]Ga-PSMA/[18F]FDG SUVmean比值(p=0.021)与PSA30缓解显著相关,[68Ga]Ga-PSMA-11 SUVmean在多因素模型中亦显著。
- ROC分析显示[68Ga]Ga-PSMA-11 SUVmean最佳截断值为10.23(AUC=0.741),PSMA/FDG SUVmean比值最佳截断值为2.08(AUC=0.727)。
- 放射学PFS单因素分析中,高ALP(p=0.023)、[68Ga]Ga-PSMA-11 MTV(p=0.011)、[68Ga]Ga-PSMA-11 TLU(p=0.015)和[18F]FDG MTV(p=0.013)与较短rPFS显著相关,[68Ga]Ga-PSMA-11 MTV在多因素模型中与rPFS呈边缘关联(p=0.061)。
- OS单因素分析中,治疗前血红蛋白(p=0.008)、ALP(p=0.018)、PSA(p=0.023)、[68Ga]Ga-PSMA-11 MTV(p=0.003)、[68Ga]Ga-PSMA-11 TLU(p=0.025)和[18F]FDG MTV(p=0.024)与OS相关,但多因素分析未确定OS的独立预测因素。
关键数值与推荐
- PSA30缓解定义为PSA下降≥30%,PSA50缓解定义为下降≥50%。
- 影像学缓解根据RECIST 1.1和/或PSMA PET进展(PPP)标准评估。
- [68Ga]Ga-PSMA-11 SUVmean预测PSA30缓解的最佳截断值为10.23(AUC=0.741)。
- [68Ga]Ga-PSMA/[18F]FDG SUVmean比值预测PSA30缓解的最佳截断值为2.08(AUC=0.727)。
临床怎么用
- 对于FDG阳性mCRPC患者,可参考基线[68Ga]Ga-PSMA-11 SUVmean及PSMA/FDG SUVmean比值辅助筛选可能从[177Lu]Lu-PSMA-I&T治疗中获得PSA30缓解的患者。
- 基线肿瘤负荷参数(PSMA MTV、PSMA TLU、FDG MTV)及ALP、血红蛋白、PSA等指标可用于预后评估。
局限性
- 回顾性研究,样本量较小(25例)。
- 多因素分析未确定OS的独立预测因素。
- 研究为初步结果,结论需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little is known about predictors of response to radionuclide therapy with PSMA-ligands in patients with [18F]FDG-positive metastatic castration-resistant prostate cancer (mCRPC). We assessed the correlation between baseline characteristics, including dual tracer PET parameters, and response to [177Lu]Lu-PSMA-I&T in a cohort of patients with [18F]FDG-positive mCRPC. Prognostic factors related to progression-free survival (PFS) and overall survival (OS) were also investigated. METHODS: mCRPC patients who underwent [68Ga]Ga-PSMA-11 and [18F]FDG PET/CT prior to [177Lu]Lu-PSMA-I&T were retrospectively evaluated. Only [18F]FDG-positive patients were included in the analysis. A semi-automatic segmentation tool was applied to measure the whole-body maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), metabolic tumor volume (MTV), and total lesion uptake (TLU) on both PET/CTs. PSA response was defined as ≥ 30% and ≥ 50% decline. Imaging response, assessed two months after the last cycle, was defined according to RECIST 1.1 and/or PSMA PET progression (PPP) criteria. Clinical, biochemical, and imaging-based factors were correlated to response to treatment, PFS, and OS. RESULTS: Twenty-five [18F]FDG-positive patients who received [177Lu]Lu-PSMA-I&T were included. PSA30 and PSA50 responses were achieved in 11/25 (44%) and in 9/25 (36%) patients, respectively. In the univariate analysis [68Ga]Ga-PSMA-11 SUVmean (p = 0.022) and [68Ga]Ga-PSMA/[18F]FDG SUVmean ratio (p = 0.021) were significantly associated with PSA30 response. [68Ga]Ga-PSMA-11 SUVmean was also significant in the multivariate model. ROC analysis indicated an optimal [68Ga]Ga-PSMA-11 SUVmean cutoff value of 10.23 (AUC = 0.741), and a best discriminating [68Ga]Ga-PSMA/[18F]FDG SUVmean cutoff ratio of 2.08 (AUC = 0.727). In the univariate analysis for radiological PFS (rPFS), high ALP (p = 0.023), [68Ga]Ga-PSMA-11 MTV (p = 0.011), [68Ga]Ga-PSMA-11 TLU (p = 0.015), and [18F]FDG MTV (p = 0.013) were significantly associated with shorter rPFS. [68Ga]Ga-PSMA-11 MTV showed a borderline association with rPFS in the multivariate model (p = 0.061). Hemoglobin levels (p = 0.008), ALP (p = 0.018) and PSA (p = 0.023) values before treatment were associated with OS, as well as [68Ga]Ga-PSMA-11 MTV (p = 0.003), [68Ga]Ga-PSMA-11 TLU (p = 0.025), and [18F]FDG MTV (p = 0.024). However, no independent predictors of OS were identified in the multivariate analysis. CONCLUSIONS: Our preliminary results suggest that a whole-body [68Ga]Ga-PSMA-11 SUVmean higher than 10 and a [68Ga]Ga-PSMA-11/[18F]FDG SUVmean ratio > 2 may serve as useful predictors for identifying patients likely to achieve at least a 30% reduction in PSA levels, even among [18F]FDG-positive mCRPC patients. Furthermore, our findings support the prognostic significance of tumor burden either calculated by imaging-based volumetric parameters or by known biochemical markers of disease.
引用
- Santo G, di Santo G, Kronthaler A, et al. Real-world outcomes of [177Lu]Lu-PSMA-I&T in [18F]FDG-positive metastatic castration-resistant prostate cancer: factors related to response and survival. Eur J Nucl Med Mol Imaging. 2026. PMID: 42249939. doi:10.1007/s00259-026-07972-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。